Aug 21, 2015 by David WGlaxoSmithKline: Buy or Bye?With all the recent news, is the London-based pharmaceutical giant a buy now?
Aug 19, 2015 by David WDividend Investors Find the GlaxoSmithKline Yield Hard to Resist Regardless of inconsistent earnings from Glaxo, the 5.6% dividend still appeals to those seeking above-average payouts. Is the payout sustainable?
Aug 11, 2015 by David WPfizer Is in Talks to Acquire GlaxoSmithKlinePfizer is among several potential bidders rumored to be in talks with the London-based pharmaceutical giant regarding a possible takeover.
Aug 8, 2015 by David WGlaxoSmithKline Taking a Bite Out of MalariaA new malaria drug, 30 years in the making, from pharmaceutical giant GlaxoSmithKline receives critical scientific approval; immunization programs expected to start next year.
Aug 4, 2015 by David WAre Things Looking Up for GlaxoSmithKline? New drugs from the Novartis transaction help offset Advair’s declining sales; CEO highlights London-based pharma giant’s future drug pipeline.
Jul 21, 2015 by David WIs Johnson & Johnson a Buy Now?Can J&J’s healthy dividend, improved guidance, and new drugs offset middling quarterly results, patent cliffs, and legal concerns?
Jul 14, 2015 by David WIs this FBI Investigation a Threat to Johnson & Johnson?The FBI is investigating a surgical device and its biggest seller: Johnson & Johnson
Jul 7, 2015 by David WWill Patent Cliff Concerns Impact Johnson & Johnson?Drugmakers face perilous sales drops upon patent expiry -- should J&J be worried?
Jun 18, 2015 by David WIs Johnson & Johnson's Future on the Fast Track?Is the pharma giant’s road map to industry-leading growth rates sustainable?
Jun 13, 2015 by David WThe 1 Johnson & Johnson Number You Should KnowThis pharmaceutical giant is in elite company.
